Boston Scientific Aktie News

MARLBOROUGH, Mass. , July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m.

Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.

Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-covered dividends. Both carry A/A+ rated balance sheets and have potential for strong total returns with a solid starting yield.

Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to the launch of new products, which have enhanced sales growth and widened profit margins.

Analysts have been cutting their estimates for companies' sales and profits, but there are always exceptions to trends.

Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY revenue growth, strong margins, and EPS beating expectations by $0.08. Organic growth and strategic acquisitions fuel BSX's expansion, supported by a diverse portfolio and active venture investments.

Boston Scientific Corporation (NYSE:BSX ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 8:01 AM ET Company Participants Michael Mahoney - Chairman and Chief Executive Officer Kenneth Stein - Senior Vice President and Global Chief Medical Officer Conference Call Participants Lee Hambright - Sanford C. Bernstein & Co., LLC Lee Hambright Okay.

Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.